These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 25626655

  • 1. Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil.
    Toledo Junior A, Daher AB, Amaral TA, Carvalho SF, Romero GA, Rabello A.
    Rev Soc Bras Med Trop; 2014; 47(6):756-62. PubMed ID: 25626655
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
    Shanehsaz SM, Ishkhanian S.
    Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ, Aminjavaheri M.
    Eur J Dermatol; 2003 Jul; 13(1):40-3. PubMed ID: 12609780
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil.
    Teixeira AC, Paes MG, Guerra Jde O, Prata A, Silva-Vergara ML.
    Rev Inst Med Trop Sao Paulo; 2008 Jul; 50(3):157-60. PubMed ID: 18604416
    [Abstract] [Full Text] [Related]

  • 11. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
    Ramalho DB, Silva RED, Senna MCR, Moreira HSA, Pedras MJ, Avelar DM, Saraiva L, Rabello A, Cota G.
    Mem Inst Oswaldo Cruz; 2018 Jun 21; 113(9):e180200. PubMed ID: 29947651
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R.
    Acta Trop; 2004 Jul 21; 91(2):153-60. PubMed ID: 15234664
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
    Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A.
    Ann Trop Med Parasitol; 2003 Jul 15; 97(5):493-8. PubMed ID: 12930612
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil.
    Lyra MR, Oliveira LFA, Schubach AO, Sampaio RNR, Rodrigues BC, Hueb M, Cota G, Silva RE, Francesconi F, Pompilio MA, França AO, Amato VS, Souza RM, Oliveira RVC, Valete CM, Pimentel MIF.
    Clin Infect Dis; 2023 Aug 22; 77(4):574-582. PubMed ID: 37100061
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
    Berger BA, Cossio A, Saravia NG, Castro MDM, Prada S, Bartlett AH, Pho MT.
    PLoS Negl Trop Dis; 2017 Apr 22; 11(4):e0005459. PubMed ID: 28384261
    [Abstract] [Full Text] [Related]

  • 18. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
    Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, Tehrani S, Dowlati Y, Firooz A.
    PLoS One; 2013 Apr 22; 8(6):e66123. PubMed ID: 23826087
    [Abstract] [Full Text] [Related]

  • 19. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S, Marr JJ.
    N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379
    [Abstract] [Full Text] [Related]

  • 20. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.
    Silva RE, Toledo A, Senna MC, Rabello A, Cota G.
    Mem Inst Oswaldo Cruz; 2016 Aug 12; 111(8):512-6. PubMed ID: 27508321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.